Stanniocalcin 1 is a prognostic biomarker in glioma

Luo,Weijian; Chen,Dong; Wang,Hao; Hu,Jiliang

doi:10.3892/ol.2020.11792

Stanniocalcin 1 is a prognostic biomarker in glioma

Authors:
- Weijian Luo
- Dong Chen
- Hao Wang
- Jiliang Hu
View Affiliations

Affiliations: Department of Neurosurgery, Shenzhen People's Hospital, Second Clinical Medical College of Ji'nan University, Shenzhen, Guangdong 518020, P.R. China
Published online on: July 1, 2020 https://doi.org/10.3892/ol.2020.11792
Pages: 2248-2256
Copyright: © Luo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant gliomas are the most common type of primary malignancy of the central nervous system with a poor prognosis. Stanniocalcin 1 (STC1) is closely associated with tumor genesis and development. However, its role in the development and progression of glioma is poorly understood. In silico analysis, The Cancer Genome Atlas (TCGA), Chinese Glioma Genome Atlas (CGGA), Rembrandt and GSE16011 datasets were used to assess the expression levels of STC1 in non‑tumor brain tissues and gliomas. Moreover, reverse transcription‑quantitative PCR and immunohistochemistry were used to detect STC1 expression in tumor tissues collected in the Department of Neurosurgery of Shenzhen People's Hospital (Shenzhen, China). The association between STC1 expression and different molecular pathological features was analyzed in four public datasets, as well as via Kaplan‑Meier analysis. Furthermore, normalized mRNA expression in TCGA was used to perform Gene Ontology analysis. It was revealed that STC1 expression was significantly elevated in glioma tissues compared with the non‑tumor brain tissues, both in silico analysis and via cohort validation. According to TCGA, CGGA, Rembrandt and GSE16011 datasets, it was identified that STC1 expression was increased in high grade glioma compared with low grade glioma. In addition, the results indicated STC1 expression was enriched in the isocitrate dehydrogenase (IDH) wild‑type and mesenchymal subtype in TCGA, GSE16011 and Rembrandt datasets. Moreover, it was demonstrated that patients with higher STC1 expression exhibited shorter overall survival times compared with those with lower STC1 expression using Kaplan‑Meier analysis, according to both the public datasets and validation cohort. Furthermore, the results of the Gene Ontology analysis demonstrated that STC1 was primarily involved in the reorganization of extracellular matrix and was significantly correlated with invasive‑related proteins. Therefore, the present results indicate that STC1 was upregulated in glioma tissues and may represent a prognostic biomarker in patients with glioma.

View Figures

View References

1	Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol. 20 (Suppl 4):iv1–iv86. 2018. View Article : Google Scholar : PubMed/NCBI
2	Albain KS, Swann RS, Rusch VW, Turrisi AT III, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, et al: Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: A phase III randomised controlled trial. Lancet. 374:379–386. 2009. View Article : Google Scholar : PubMed/NCBI
3	Ostrom QT, Cote DJ, Ascha M, Kruchko C and Barnholtz-Sloan JS: Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA Oncol. 4:1254–1262. 2018. View Article : Google Scholar : PubMed/NCBI
4	Bralten LB and French PJ: Genetic alterations in glioma. Cancers (Basel). 3:1129–1140. 2011. View Article : Google Scholar : PubMed/NCBI
5	Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM, Maiorka PC, et al: Genetic pathways to glioblastoma: A population-based study. Cancer Res. 64:6892–6899. 2004. View Article : Google Scholar : PubMed/NCBI
6	Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, et al: p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature. 455:1129–1133. 2008. View Article : Google Scholar : PubMed/NCBI
7	Chou MY, Lin CH, Chao PL, Hung JC, Cruz SA and Hwang PP: Stanniocalcin-1 controls ion regulation functions of ion-transporting epithelium other than calcium balance. Int J Biol Sci. 11:122–132. 2015. View Article : Google Scholar : PubMed/NCBI
8	Hayase S, Sasaki Y, Matsubara T, Seo D, Miyakoshi M, Murata T, Ozaki T, Kakudo K, Kumamoto K, Ylaya K, et al: Expression of stanniocalcin 1 in thyroid side population cells and thyroid cancer cells. Thyroid. 25:425–436. 2015. View Article : Google Scholar : PubMed/NCBI
9	Zhou H, Li YY, Zhang WQ, Lin D, Zhang WM and Dong WD: Expression of stanniocalcin-1 and stanniocalcin-2 in laryngeal squamous cell carcinoma and correlations with clinical and pathological parameters. PLoS One. 9:e954662014. View Article : Google Scholar : PubMed/NCBI
10	Song H, Xu B and Yi J: Clinical significance of stanniocalcin-1 detected in peripheral blood and bone marrow of esophageal squamous cell carcinoma patients. J Exp Clin Cancer Res. 31:352012. View Article : Google Scholar : PubMed/NCBI
11	Du YZ, Gu XH, Li L and Gao F: The diagnostic value of circulating stanniocalcin-1 mRNA in non-small cell lung cancer. J Surg Oncol. 104:836–840. 2011. View Article : Google Scholar : PubMed/NCBI
12	Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, Zheng J, Bast RC, Lin SH and Liu J: Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst. 102:812–827. 2010. View Article : Google Scholar : PubMed/NCBI
13	Chan KK, Leung CO, Wong CC, Ho DW, Chok KS, Lai CL, Ng IO and Lo RC: Secretory stanniocalcin 1 promotes metastasis of hepatocellular carcinoma through activation of JNK signaling pathway. Cancer Lett. 403:330–338. 2017. View Article : Google Scholar : PubMed/NCBI
14	Su J, Guo B, Zhang T, Wang K, Li X and Liang G: Stanniocalcin-1, a new biomarker of glioma progression, is associated with prognosis of patients. Tumour Biol. 36:6333–6339. 2015. View Article : Google Scholar : PubMed/NCBI
15	Li Y, He ZC, Zhang XN, Liu Q, Chen C, Zhu Z, Chen Q, Shi Y, Yao XH, Cui YH, et al: Stanniocalcin-1 augments stem-like traits of glioblastoma cells through binding and activating NOTCH1. Cancer Lett. 416:66–74. 2018. View Article : Google Scholar : PubMed/NCBI
16	Bowman RL, Wang Q, Carro A, Verhaak RG and Squatrito M: GlioVis data portal for visualization and analysis of brain tumor expression datasets. Neuro Oncol. 19:139–141. 2017. View Article : Google Scholar : PubMed/NCBI
17	Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, Duijm JE, Daemen A, Bleeker FE, Bralten LB, Kloosterhof NK, et al: Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. 69:9065–9072. 2009. View Article : Google Scholar : PubMed/NCBI
18	Hu H, Mu Q, Bao Z, Chen Y, Liu Y, Chen J, Wang K, Wang Z, Nam Y, Jiang B, et al: Mutational landscape of secondary glioblastoma guides MET-targeted trial in brain tumor. Cell. 175:1665–1678.e18. 2018. View Article : Google Scholar : PubMed/NCBI
19	Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 world health organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
20	Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 17:98–110. 2010. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
23	Pekmezci M, Rice T, Molinaro AM, Walsh KM, Decker PA, Hansen H, Sicotte H, Kollmeyer TM, McCoy LS, Sarkar G, et al: Adult infiltrating gliomas with WHO 2016 integrated diagnosis: Additional prognostic roles of ATRX and TERT. Acta Neuropathol. 133:1001–1016. 2017. View Article : Google Scholar : PubMed/NCBI
24	Shen R, Mo Q, Schultz N, Seshan VE, Olshen AB, Huse J, Ladanyi M and Sander C: Integrative subtype discovery in glioblastoma using icluster. PLoS One. 7:e352362012. View Article : Google Scholar : PubMed/NCBI
25	Morokoff A, Ng W, Gogos A and Kaye AH: Molecular subtypes, stem cells and heterogeneity: Implications for personalised therapy in glioma. J Clin Neurosci. 22:1219–1226. 2015. View Article : Google Scholar : PubMed/NCBI
26	Ramirez YP, Weatherbee JL, Wheelhouse RT and Ross AH: Glioblastoma multiforme therapy and mechanisms of resistance. Pharmaceuticals (Basel). 6:1475–1506. 2013. View Article : Google Scholar : PubMed/NCBI
27	Kikuchi M, Nakano Y, Nambo Y, Haneda S, Matsui M, Miyake Y, Macleod JN, Nagaoka K and Imakawa K: Production of calcium maintenance factor stanniocalcin-1 (STC1) by the equine endometrium during the early pregnant period. J Reprod Dev. 57:203–211. 2011. View Article : Google Scholar : PubMed/NCBI
28	Du YZ, Gu XH, Cheng SF, Li L, Liu H, Hu LP and Gao F: The oncogenetic role of stanniocalcin 1 in lung adenocarcinoma: A promising serum candidate biomarker for tracking lung adenocarcinoma progression. Tumour Biol. 37:5633–5644. 2016. View Article : Google Scholar : PubMed/NCBI
29	Brantley KD, Kjaersgaard A, Cronin-Fenton D, Yacoub R, Nielsen AS, Lauridsen KL, Hamilton-Dutoit S and Lash TL: Stanniocalcin expression as a predictor of late breast cancer recurrence. Cancer Epidemiol Biomarkers Prev. 27:653–659. 2018. View Article : Google Scholar : PubMed/NCBI
30	Wang Y, Qi Z, Zhou M, Yang W, Hu R, Li G, Ma X and Zhang Z: Stanniocalcin1 promotes cell proliferation, chemoresistance and metastasis in hypoxic gastric cancer cells via Bcl2. Oncol Rep. 41:1998–2008. 2019.PubMed/NCBI
31	Leung CC and Wong CK: Effects of STC1 overexpression on tumorigenicity and metabolism of hepatocellular carcinoma. Oncotarget. 9:6852–6861. 2018. View Article : Google Scholar : PubMed/NCBI
32	Shirakawa M, Fujiwara Y, Sugita Y, Moon JH, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Mori M and Doki Y: Assessment of stanniocalcin-1 as a prognostic marker in human esophageal squamous cell carcinoma. Oncol Rep. 27:940–946. 2012. View Article : Google Scholar : PubMed/NCBI
33	Li K, Dong D, Yao L, Dai D, Gu X and Guo L: Identification of STC1 as an beta-amyloid activated gene in human brain microvascular endothelial cells using cDNA microarray. Biochem Biophys Res Commun. 376:399–403. 2008. View Article : Google Scholar : PubMed/NCBI
34	Durukan Tolvanen A, Westberg JA, Serlachius M, Chang AC, Reddel RR, Andersson LC and Tatlisumak T: Stanniocalcin 1 is important for poststroke functionality, but dispensable for ischemic tolerance. Neuroscience. 229:49–54. 2013. View Article : Google Scholar : PubMed/NCBI
35	Ito Y, Zemans R, Correll K, Yang IV, Ahmad A, Gao B and Mason RJ: Stanniocalcin-1 is induced by hypoxia inducible factor in rat alveolar epithelial cells. Biochem Biophys Res Commun. 452:1091–1097. 2014. View Article : Google Scholar : PubMed/NCBI
36	Monteiro AR, Hill R, Pilkington GJ and Madureira PA: The Role of Hypoxia in Glioblastoma Invasion. Cells. 6:E452017. View Article : Google Scholar : PubMed/NCBI
37	Yeung HY, Lai KP, Chan HY, Mak NK, Wagner GF and Wong CK: Hypoxia-inducible factor-1-mediated activation of stanniocalcin-1 in human cancer cells. Endocrinology. 146:4951–4960. 2005. View Article : Google Scholar : PubMed/NCBI
38	Jensen RL: Brain tumor hypoxia: Tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol. 92:317–335. 2009. View Article : Google Scholar : PubMed/NCBI